

## PRESS RELEASE FROM FUTURE SCIENCE GROUP

September 2012

Contact: Victoria Lane,

Senior Manager, Future Science Group.

T: +44 (0) 20 8371 6090 E: v.lane@futuremedicine.com

### ***CNS Oncology* journal launched by Future Science Group**

Future Science Group, publishers of the internationally acclaimed journals *Pharmacogenomics* (IF: 3.974) and *Nanomedicine* (IF: 5.055), have launched the first issue of their new bimonthly title, *CNS Oncology*.

Senior Editors, Henry S Friedman (Duke University Medical Center, USA) and Alba A Brandes (Azienda USL of Bologna, Italy), envisage the new addition to Future Science Group's portfolio will play a major role in disseminating current opinion on the treatment of patients with brain tumors to a broad constellation of physicians and scientists involved in the neuro-oncology field. The Senior Editors are supported by a team of six Associate Editors, together with an Advisory Panel of 32 international experts.

*CNS Oncology* will provide oncologists with updates on key issues in screening, diagnosis, imaging, surgery, radiation, chemotherapy, targeted therapeutics and palliative care by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. Elisa Manzotti, Publisher at Future Science Group said, "We are delighted with the launch issue *CNS Oncology*, which brings together contributions from global opinion leaders in this vital specialty field. It is an excellent contribution to the oncology literature and a testament to the efforts of all involved in this new endeavor."

Highlights from the first issue include a case report on brain metastases as a cause of malignant cerebrospinal fluid ascites by WH Ng and coworkers of the National Neuroscience Institute (Singapore) and a review on the state of the art of glioblastoma care by Sean A Grimm (Northwestern University, IL, USA) and Marc C. Chamberlain (Seattle Cancer Care Alliance, WA, USA).

*CNS Oncology* will take the lead in generating discourse and debate with the aim of improving outcome for brain tumor patients. In their foreword to the issue, the Senior Editors explain, "We welcome submissions on all topics of neuro-oncology and are particularly interested in publishing articles that will have opposing views allowing generation of meaningful discussions. In other words, controversial topics are particularly welcome as they frequently lead to the most important discussions in any given field."

*CNS Oncology* is latest of Future Science Group's recent launches to focus on clinical cancer management and follows new titles for 2012, *Breast Cancer Management* and *Lung Cancer Management*. Another edition to this exciting portfolio, *International Journal of Hematologic Oncology*, will be launched in October.

The full contents list for the launch issue can be viewed at  
<http://www.futuremedicine.com/toc/cns/1/1>

The Editorial Office is now actively soliciting contributions of original research, reviews and commentary articles for *CNS Oncology*. For a full range of the exciting new article types please see our [Author Guidelines](#). In particular, we would like to encourage clinical studies in any aspect of CNS oncology. For more details and to contribute, please contact the Launch Editor, [Victoria Lane](#)

### **About the Senior Editors**

Henry S. Friedman is the James B. Powell, Jr. Professor of Neuro-Oncology at Duke University Medical Center. He is internationally recognized for his work as an educator, clinician, and laboratory/clinical investigator in both pediatric and adult brain and spinal cord tumors. He received his MD from Upstate Medical Center in Syracuse, New York in May of 1977 and stayed at that institution for pediatric and pediatric hematology-oncology training. He trained in neuro-oncology at Duke University Medical Center and joined the faculty at that institution in 1983. He has published over 500 articles in peer reviewed professional journals. He currently serves as the Co-Deputy Director of The Preston Robert Tisch Brain Tumor Center at Duke.

Alba A Brandes is Chief of the Medical Oncology Department, Bellaria - Maggiore Hospitals, Azienda USL, Italy, and has authored more than 180 peer-reviewed articles on tumors of the brain, breast, lung and ovary. She has authored over 300 abstracts and book chapters. In 2001, Dr Brandes was knighted with the title of Cavaliere della Repubblica by the President of the Republic of Italy for her activities in oncology research.

### **About Future Science Group**

Future Medicine Ltd has developed an innovative publishing portfolio to reflect post-genomic medicine. The company is part of the London-based Future Science Group, alongside sister imprints Future Science Ltd and Expert Reviews Ltd. The Future Science Group provides research professionals and clinicians with a unique source of objective, cutting-edge information on exciting emerging trends in science and medicine. Please see [www.future-science-group.com](http://www.future-science-group.com) and [www.futuremedicine.com](http://www.futuremedicine.com) for more information.

If you are interested in receiving a free 30-day online trial to evaluate the journal's content please contact [info@futuremedicine.com](mailto:info@futuremedicine.com), quoting CNS12.

For further information on *CNS Oncology* please contact  
Victoria Lane,  
Senior Manager, Future Science Group.  
T: +44 (0) 20 8371 6090 E: [v.lane@futuremedicine.com](mailto:v.lane@futuremedicine.com)

- - - ENDS - - -